Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: GlobeNewswire
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for active traders seeking amplified exposure to innovative companies at the forefront of biotechnology and life sciences. MRNX is designed for traders seeking magnified, short-term bullish exposure to Moderna, Inc. (NASDAQ: MRNA), a biotechnology company known for its messenger RNA (mRNA)–based medicines and vaccine development platform. By seeking to deliver 200% of the daily percentage change in the share price of Moderna, Inc., the Fund allows investors to express tactical upside views on MRNA within the accessibility and transparency of an exchange-traded fund. Investment Objective The Fund seeks daily investment results, before fees and expenses, of two times (200%) the daily percentage change in the share price of Moderna, Inc. (NASDAQ: MRNA). The Fund does not seek to achieve it
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Moderna (NASDAQ:MRNA) had its "underperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Moderna (NASDAQ:MRNA) had its "hold" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Moderna (NASDAQ:MRNA) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $25.00 price target on the stock.MarketBeat
- Moderna (MRNA) Touches 52-Week High on Strong Clinical Results [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 2/6/26 - Form SCHEDULE
- 2/5/26 - Form SCHEDULE
- 1/12/26 - Form 8-K
- MRNA's page on the SEC website